Expression of type VI collagen in the developing mouse heart

Area of Science:

• Cardiovascular Development
• Extracellular Matrix Biology
• Congenital Heart Defect Etiology

Background:

• Embryonic atrioventricular (AV) endocardial cushions are crucial for heart valve and septa formation.
• Abnormal AV valve development is linked to congenital heart defects, especially in trisomy 21 (Down syndrome).
• Genes for type VI collagen alpha1(VI) and alpha2(VI) chains are on chromosome 21, implicating them in trisomy 21-associated heart defects.

Purpose of the Study:

• To investigate the role of type VI collagen in embryonic heart valve development.
• To determine the spatial and temporal expression patterns of type VI collagen mRNA and protein in the developing mouse heart.

Main Methods:

• Ribonuclease protection assay to detect type VI collagen transcripts (alpha1(VI), alpha2(VI), alpha3(VI)).
• In situ hybridization to visualize transcript localization within AV valves.
• Immunohistochemistry to confirm protein localization in endocardial cushions.

Main Results:

• Cardiac expression of all three type VI collagen transcripts (alpha1(VI), alpha2(VI), alpha3(VI)) begins at embryonic days 11-11.5.
• Coordinated expression of type VI collagen chains occurs in AV valves from embryonic day 11.5 through the neonatal period.
• Type VI collagen protein is concentrated in endocardial cushions throughout valve development.

Conclusions:

• Type VI collagen is expressed in the developing AV canal in a pattern supporting mesenchymal cell migration and proliferation.
• These findings suggest type VI collagen is essential for the morphogenesis of AV endocardial cushions into heart valves and septa.
• This research provides a foundation for understanding type VI collagen's role in congenital heart defects, particularly those associated with trisomy 21.